Consulting Examples

Every company is different. They have different strengths, vulnerabilities, and opportunities. Our comprehensive view of molecular medicine is applicable to many different situations. Molecular medicine will have an impact on even the most well-established and successful companies. If you're not paying attention or not prepared, your markets can change very quickly. GHS can help you stay ahead of these changes.

Since our work usually involves high level corporate strategy and new market entry, we are under confidentiality agreements and our examples below describe limited details. However, we believe that they are illustrative of GHS's focus and activities. We think you might see situations comparable to yours and look forward to hearing from you.

:: Strategic Guidance
For a Fortune 500 company: On-going strategic input, review, and guidance for senior executives around the company's utilization of the new science of molecular medicine to reduce healthcare costs for their covered populations. The company has implemented major changes in focus, along with new initiatives which will strengthen their competitive position.

:: Executive Briefings and Discussions
For several Fortune 500 companies: Executive briefings and strategy discussions to introduce personalized health and wellness markets to them, facilitate internal dialogue, and allow them to begin to consider options for entering these markets.

:: Business Planning
For a venture-backed U.S. diagnostics company: Business strategy development around market entry, review and selection of their most commercially viable offerings, quick paths to revenues, and development of their business plan. Led to successfully attaining next round of funding and moving forward at higher valuation.

:: Strategy Review
For a major venture capital firm: Review of and comment on their internal plan and criteria for investing their new fund focused on diagnostics.

:: Due Diligence
For a Fortune 500 company: In-depth scientific, competitive, commercial, and market due diligence around a major initiative with a potential partner. Changed their direction towards a more commercially viable arrangement.

:: Market Introduction
For a European diagnostic firm: Strategy development, offering diagnostic and disease category selection and detailed operational planning for entry into U.S. markets. Specific issues dealt with included regulatory pathways, sales and marketing, payer strategies, reimbursement, interaction with patient advocacy groups, and communications.

:: Market Expansion
For a major spa: Consultation on expanding their market scope through branded consumer wellness products.

:: Partnering Strategies
For an early-stage molecular diagnostic company, developed and implemented a strategy for reduced equity dilution and quicker time to significant sales volume through innovative partnering arrangements.

:: Consumer Genomics Standards
GHS participates in industry organizations and serves on an industry standards/self regulatory advisory committee.

Let us explore with you, how your company will be affected by personalized medicine and how to use the changing marketplace to your advantage. We understand how the disparate pieces of these new markets are related, and can help your company take advantage of emerging opportunities. Our clear insights have helped make our clients to become successful in this new space.

Please contact GHS to discuss how we might work together.